Veregen® is an ointment used to treat external genital warts. In the USA, Germany, Austria, Spain, Switzerland, Serbia, the Netherlands and Taiwan Veregen® is already marketed by our partners. Sales and marketing partnerships are also in place for this drug in a large number of other countries in Europe, Asia and America. An overview of our partners can be found here. The sales generated with Veregen® are continually rising and making a valuable contribution to financing the Company.
As an innovative drug, Veregen® is based on a defined extract from green tea leaves obtained in a highly complex and specifically developed process
Medigene in-licensed the basic rights to the active ingredient of Veregen® in 1999 and then completed the clinical development of Veregen®. Subsequently, Medigene successfully obtained a marketing authorization by the approval process of the US Food and Drug Administration (FDA). Veregen® is the first, and to date one of a very small number of innovative plant-based drug approved by the FDA. Furthermore, Medigene is the first German biotech company to have a drug on the US market.
Veregen® was developed by Medigene AG and is currently available in Germany, Austria, Spain, Switzerland, Serbia (since April 2013), the Netherlands (since July 2013) and Taiwan (since October 2013). Within the EU, Veregen® has been approved in Belgium, Bulgaria, Cyprus, the Czech Republic, Denmark, Finland, France, Hungary, Luxembourg, Norway, Poland, Romania, Slovakia, Slovenia and Sweden. Market approval for Greece is expected in the next few months. Outside the EU, Veregen® has been approved in Israel and Taiwan. Additionally, market authorisation applications have been submitted by partner companies in Canada, Mexico and Turkey. These are being evaluated by the regulatory authorities at present.
Veregen® is also listed in recognized treatment guidelines. The US Center for Disease Control and Prevention In its current treatment guidelines for sexually transmitted diseases, recommends Sinecatechins 15% ointment (Veregen®) as a possible option for treating genital warts. In addition, the “2012 European Guideline for the Management of Anogenital Warts” includes Sinecatechins 10% & 15% ointment (Veregen®) as a recommended treatment option for genital warts.
Further market launches of Veregen®, as well as the conclusion of further marketing partnerships are planned.
Veregen® is a trademark of Medigene AG.
Polyphenon E® is a trademark of Mitsui Norin Co., Ltd.